Long-term treatment with recombinant Interferon alpha-2b prolongs survival of asymptomatic HTV-infected individuals

Biotherapy

Volumn 10, Issue 2, 1997, Pages 107-113

  Rivero, J ^a,b   Fraga, M ^a   Cancio, I ^a   Cuervo, J ^a   Lopez Saura P ^a  

^a Sanatoria Santiago de Las Vegas   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Hiv infection; Randomized clinical trial; Recombinant interferon alpha 2b; Survival

Indexed keywords

HEBERON ALPHA 2B; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; STATISTICS; SURVIVAL TIME; TONGUE CARCINOMA; UTERINE CERVIX CARCINOMA; VIRUS REPLICATION;

EID: 0030779085     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02678537     Document Type: Article

References (36)

1. Mulder JW, Cooper DA & Mathiesen L, et al. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017). AIDS 1994; 8(3): 313-21.
2. Ragni MV, Amato DA & LoFaro ML et al. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hémophilie and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups. Blood 1995; 85(9): 233746.
3. Andrieu JM, Lu W & Levy R. Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis 1995; 171(3): 523-30.
4. Mannucci PM, Gringeri A & Savidge G et al. Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. Br J Haematol 1994; 86(1): 174-9.
5. Aboulker JP & Swart AM. Preliminary analysis of the Concorde trial. Lancet 1993; 341: 889-890.
6. Volberding PA, Lagakos SW & Grimes JM et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995; 333(7): 401-7.
7. Volberding PA, Lagakos SW & Grimes JM et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. J Amer Med Associât 1994; 272(6): 437
8. loannidis JP, Cappelleri JC & Lau J et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defming illness. Ann Intern Med 1995; 122(11): 856-66.
9. Lenderking WR, Gelber RD & Cotton DJ et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 1994; 330(11):738-43.
10. Zaretsky MD. AZT toxicity and AIDS prophylaxis: is AZT beneficial for HIV+ asymptomatic persons with 500 or more T4 cells per cubic millimeter? Genetica 1995; 95(1-3): 91101.
11. Pitha PM. Multiple effects of interferon on the replication of human immunodeficiency virus type 1. Antiviral Res 1994; 24(2-3): 205-19.
12. Francis ML, Meltzer MS & Gendelman HE. Interferons in the persistence, pathogenesis, and treatment of HIV infection. AIDS Res Human Retroviruses 1992: 8: 199-207.
13. Tappero JW, Conant MA, Wolfe SF & Berger TG. Kaposi's sarcoma. Epidemiology, pathogenesis, histology, clinical spec-trum, staging criteria and therapy. J Amer Acad Dermatol 1993 ; 28: 371-95
14. Rivero J, Limonta M, Aguilera A, Fraga M & Lopez-Saura P. Use of recombinant interferon-alpha in human immunodeficiency virus (HlV)-infected individuals. Biotherapy 1995; 8(1):23-31.
15. Revision of the CDC surveillance case definition for Acquired Immunodeficiency Syndrome. Council of State and Territorial Epidemiologist; AIDS program, Center for Infectious Disease. MMWR 1987; 36: 1S-15S.
16. Scheper-Hughes N. AIDS, public health and human rights in Cuba. Lancet 1993; 342: 965-967.
17. Kaplan EL & Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Ass 1958; 53: 457-481.
18. Friedman LM, Furberg CD & DeMets DL (eds). Fundamentals of Clinical Trials: Chapter 14. Survival Analysis, 2nd. edition, PSG Publishing Company, INC, Littleton, MA, 1985 pp 191-211.
19. Ezkowitz RAB, Mulliken JB & Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456.
20. Chang Y, Cesarman E & Pessin MS et al. Identification of new human herpesvirus-like KNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-69
21. Huang YQ, Li JJ & Kaplan MH et al. Human herpesviruslike nucleic acid in various forms of Kaposi's sarcoma. Lancet 1995; 345: 759-61
22. Morfeldt L & Torsander J. Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients. Scand J Infect Dis 1994; 26: 749-52
23. CostagliolaD & Mary-Krause M. Can antiviral agents decrease the occurrence of Kaposi's sarcoma? Lancet 1995; 346: 578
24. Kovacs JA, Baseler M & Dewar RJ et al. Increases in CD4 T lymphocytes with intermitent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995; 332 (9): 567-75.
25. Simberkoff MS, Hartigan PM & Hamilton JD et al. Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11(2): 142-50
26. Connor EM, Sperling RS & Gelber R et al. Reduction of maternal-infant tranmission of human immunodeficiency virus type I with zidovudine treatment. N Engl J Med 1994; 331: 1173-80
27. Zaretsky MD. AZT toxicity and AIDS prophylaxis: is AZT beneficial for HIV+ asymptomatic persons with 500 or more T4 cells per cubic millimeter? Genetica 1995; 95(1-3): 91-101
28. Volberding P. The value of the CD4+ count of 500 cells/microliters. Drugs 1995; 49 Suppl 1: 4-8
29. Kunzi MS, Farzadegan H, Margolick JB, Vlahov D & Pitha PM. Identification of human immunodeficiency virus primary isolates resistant to interferon-alpha and correlation of prevalence to disease progression. J Infect Dis 1995; 171(4): 822-8
30. Bissuel F, Trabaud MA & Leriche K et al. Tolerance of a triple combination therapy with zidovudine, didanosine and interferon-alpha in seven HIV-infected patients. AIDS 1995; 9(11): 1285
31. Garaci E, Rocchi G & Perroni L et al. Combination treatment with zidovudine, thymosin alpha-1 and interferon-alpha in human immunodeficiency virus infection. Int J Clin Lab Res 1994; 24(1): 23-8
32. Puppo F, Orlando G, Torresin A, Papa D, Balleari E, Criscuolo D & Indiveri F. Low doses of alpha interferon for the treat-ment of AIDS related syndromes: a preliminary study. Int J Immunotherapy 1988; 4:165-8.
33. Lane HC, Davey V, Kovacs JA, Feinberg J, Metcalf JA & Herpin B et al. Interferon alpha in patients with asymptomatic Human Immunodeficiency Virus (HIV) infection. A randomized, placebo-controlled trial. Ann Int Med 1990; 112: SOS-11.
34. Jordan WC. Three open-label studies of oral interferon alpha in the treatment of HIV disease. J Natl Med Assoc 1994; 86(4): 257-62.
35. Mttltbn MR, Levin DL & Freedman LS. Randomized, PlaceboControlled, Double- Blind Study of Low-Dose Oral Interferona in HTV-1 Antibody Positive Patients. J of Acquired Inmune Deficiency Syndromes 1992; 5: 1084-90.
36. Sperber SJ, Gocke DJ, Haberzettl CA & Petska S. Low-dose oral recombinant interferon-alpha-a in patients with HIV-1 infection. A blinded pilot study. AIDS 1993; 7 (5): 693-7.